BioCentury
ARTICLE | Clinical News

OMP-305B83: Phase Ia started

January 19, 2015 8:00 AM UTC

OncoMed began an open-label, dose-escalation, U.S. Phase Ia trial to evaluate 0.5, 1, 2.5, 5 and 10 mg/kg IV OMP-305B83 every 3 weeks in about 50 patients. Celgene Corp. (NASDAQ:CELG, Summit, N.J.) h...